目前，宫颈癌（CC）是全球第四种有记录的女性中广泛传播的癌症。尽管由于筛查识别和创新治疗方法，发病率和死亡率有所下降，但仍然发现了许多转移性或复发性疾病的病例。对于不适合手术和放疗等治愈性治疗的患者，姑息化疗仍然是标准治疗方法。本文旨在对 CC 治疗方法进行全面、最新的总结。作者在回顾临床研究结果的同时强调了正在进行的试验。利用生物机制靶向不同分子途径的药物，如表皮生长因子受体 (EGFR)、血管内皮生长因子 (VEGF)、哺乳动物雷帕霉素靶标 (mTOR)、聚 ADP-核糖聚合酶 (PARP) 和表观遗传生物机制的缩影和提供了有趣的研究前景。

Currently, cervical cancer (CC) is the fourth recorded widespread cancer among women globally. There are still many cases of metastatic or recurring disease discovered, despite the incidence and fatality rates declining due to screening identification and innovative treatment approaches. Palliative chemotherapy continues to be the standard of care for patients who are not contenders for curative therapies like surgery and radiotherapy. This article seeks to provide a thorough and current summary of therapies that have been looked into for the management of CC. The authors emphasize the ongoing trials while reviewing the findings of clinical research. Agents that use biological mechanisms to target different molecular pathways such as epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), mammalian target of rapamycin (mTOR), poly ADP-ribosepolymerase (PARP), and epigenetic biological mechanisms epitomize and offer intriguing research prospects.